<DOC>
	<DOCNO>NCT02958657</DOCNO>
	<brief_summary>This project aim evaluate , recent post-acute myocardial infarction ( AMI ) patient dual antiplatelet therapy , impact regular exercise training platelet aggregability correlation level platelet aggregability muscle sympathetic nerve activity ( MSNA ) .</brief_summary>
	<brief_title>Influence Exercise Training Platelet Aggregability Post-myocardial Infarction Population</brief_title>
	<detailed_description>1 . Introduction : Platelet reactivity closely involved pathophysiology acute coronary syndrome ( ACS ) . However , despite development newer effective antiplatelet drug ( among therapeutic intervention ) , risk ischemic event recurrence episode ACS still high . On hand , acute strenuous exercise , know trigger ACS , perform untrained individual , lead sympathetic hyperactivity increase platelet aggregability . Contrary finding , regular supervise exercise training lead regulation autonomic system consequent decrease incidence ACS , show previous study . However , relationship regular supervise exercise training platelet activity patient post-AMI dual antiplatelet therapy , previously study main goal present project . 2 . Objectives : This project aim evaluate , recent post-AMI patient dual antiplatelet therapy , impact regular exercise training platelet aggregability , analyze VerifyNowP2Y12® test . Secondary exploratory analysis include : 1 ) influence acute strenuous exercise platelet aggregability measure immediately two cardiopulmonary exercise testing ( CPET ) patient submit ; 2 ) correlation level platelet aggregability MSNA train control group ; 3 ) influence exercise training platelet aggregability measure Multiplate® adenosine diphosphate ( ADP ) test Multiplate® aspirin ( ASPI ) test ; 4 ) influence exercise training mean platelet volume ( MPV ) platelet count ; 5 ) influence exercise training laboratorial parameter lipid , blood glucose inflammatory activity ; 6 ) finally , primary endpoint study evaluate different prespecified subgroup diabetic , elderly , obese patient chronic kidney disease . 2.1 . Primary endpoint study : Evaluate influence regular supervise exercise training 3 month platelet aggregability , analyze VerifyNowP2Y12® test , patient recent AMI utilize dual antiplatelet therapy . 2.2 . Main secondary analysis : A . Evaluate platelet aggregability immediately acute exercise exercise training period ; propose , blood sample draw immediately first second cardiopulmonary exercise testing , train control group . B. Correlate platelet aggregability level , evaluate VerifyNowP2Y12® , Multiplate-ADP® , Multiplate-ASPI® , level MSNA . 2.3 . Other exploratory analysis : A . Evaluate primary endpoint study utilize Multiplate-ASPI® Multiplate-ADP® ; B . Evaluate MPV train control group , correlation platelet aggregability ; C. Analyze , train control group , follow parameter : Platelet count ; LDL-cholesterol ; HDL-cholesterol ; Triglycerides ; Lipid transference HDL ; Fasting glucose ; Glycated hemoglobin ; C-reactive protein ( CRP ) ultrasensitive ; B-type natriuretic peptide ( BNP ) ; Troponin Creatine Kinase MB-mass peak obtain hospitalization ; Genetic polymorphism ; Heart rate variability spontaneous baroreflex control . D. Analyze primary endpoint within follow subgroup , take account parameter obtain hospitalization : Sex ( male / female ) ; ST segment elevation myocardial infarction ( STEMI ) non-STEMI ; Basal heart rate ( &lt; 70 ≥ 70 bpm ) ; History arterial hypertension ( presence absence ) ; LDL level ( &lt; 100 ≥ 100 mg/dL ) ; Age ≥65 year &lt; 65 year ; Body Mass Index &lt; 30 ≥ 30 kg / m2 ; Creatinine clearance ( MDRD ) &lt; 60ml / min / m2 ≥ 60 ml / min / m2 ; Current smoking ; History diabetes ( present absent ) ; HbA1c &lt; 6.5 ≥ 6.5 % ; GRACE risk score ≥140 &lt; 140 ; Beta-blocker use . 3 . Methodology : This prospective , randomize study . Patients stable AMI admit Coronary Care Unit , eligible participate , randomize AMI hospitalization supervise exercise training program three month rehabilitation unit control group formally train . Patients agree participate include necessary explanation signature inform consent form . 3.a . Sample size calculation : To perform sample calculation , previously publish data wich show platelet agreeability average 32.9 ± 16 P2Y12 reaction unit ( PRU ) post-AMI patient ticagrelor utilize . For expect 35 % decrease platelet aggregability train group , take account power 80 % alpha index 0.05 , include 31 patient group require . Admitting percentage loss 40 % give difficulty inherent assessment sympathetic activity adherence training program , initial plan contemplate inclusion 90 patient study ( 45 group ) . 4 . Study design : Prospective study eligible patient uncomplicated AMI admit Coronary Care Unit randomize perform exercise training program three month untrained control group , 1:1 rate . All patient include necessary explanation sign informed consent form . The patient submit collection material laboratory evaluation include platelet aggregability test , assessment MSNA CPET 01 04 month follow-up ( end treatment ) .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Hospitalization spontaneous STEMI nonSTEMI patient older 18 year . Any condition contraindicate physical activity ; Regular exercise training practitioner prior ischemic event ; Planned revascularization follow 4 month ; Hospitalization cardiovascular event previous 12 month ; Ventricular dysfunction , define leave ventricular ejection fraction ( LVEF ) &lt; 45 % echocardiography , evaluate Simpson 's method ) ; f ) Killip class III IV ; High risk arrhythmia and/or second third degree atrioventricular block ; Diabetes mellitus require intravenous insulin therapy hospitalization ; Important chronic kidney disease , define creatinine clearance &lt; 30ml/min/m2 ( estimate MDRD formula ) ; Oral anticoagulation ; Use NSAIDs and/or dipyridamole ; Contraindication dual antiplatelet therapy ; Serum hemoglobin level &lt; 10 g/dL ; Use glycoprotein IIB/IIIA inhibitor last 48 hour ; Terminal illness ; Liver disease coagulopathy ; Refusal engage exercise training program .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Platelet function</keyword>
	<keyword>Autonomic Nervous System</keyword>
	<keyword>Multiplate® ( Multiple Electrode Aggregometry - MEA )</keyword>
	<keyword>VerifyNow®</keyword>
</DOC>